about
A questionnaire survey of stress and bullying in doctors undertaking researchAntibacterial prophylaxis after chemotherapy for solid tumors and lymphomasEurogin 2016 Roadmap: how HPV knowledge is changing screening practice.Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series.The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.Phase I trial of temozolomide using an extended continuous oral schedule.Immunotherapy for renal cell cancer.Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapyA double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimodHuman immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration.HIV-associated Hodgkin's disease.Anal intraepithelial neoplasia in HIV positive people.Current issues in the biology of AIDS-related lymphoma.Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.British HIV Association guidelines for HIV-associated malignancies 2014.Risk of cancers during interrupted antiretroviral therapy in the SMART study.Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.The management of lymphoma in the immunosuppressed patient.What can oncologists learn from HIV?Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART eraAcquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy.HIV-related lung cancer -- a growing concern?Kaposi's sarcoma as a model for cancer immunotherapy.The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma.EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.Fifty years of multicentric Castleman's disease.The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma.Paclitaxel for AIDS-associated Kaposi's sarcoma.Recent insights into the pathogenesis of Kaposi's sarcomaAIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.Comparative pharmacogenomics of antiretroviral and cytotoxic treatments.The rationale and development of new drugs to treat HIV infection.Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.Chemotherapy for advanced cholangiocarcinoma: what is standard treatment?Significance of variation within HIV, EBV, and KSHV subtypes.A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours.Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
P50
Q24680343-299DF73B-C63F-4662-80ED-E7D9CCB58B6CQ28271157-9D77D9A0-229E-4325-8E71-6EBE0049236DQ30239987-3F03EA93-0741-42FA-A965-13C6692F7B21Q33401191-FF8480A9-E9A9-436E-80CF-43F9984704E8Q33470219-1F3CE46F-FCC8-4DF6-BC35-4661F3C9110FQ33503863-032338CF-3C8B-4F65-BE06-23703B6C2B87Q33534516-D30FA874-90EC-4FB8-A14D-0C838CAAD5B8Q33618900-4DBAA5BC-AB38-47D2-BB22-BF33042F801AQ33668568-A8641993-3813-4FE8-B3F5-8D66320F94D9Q33742919-F5A018C5-9818-42DD-8AB1-7DF78B9A60AFQ34035265-BC3DE4D1-321C-4DF1-9C95-C803A8D4670CQ34392775-FB8AB844-0414-4C8E-87DB-E17498812AD2Q34459395-50EA3A30-BEFF-4FF2-A107-23C425ECFDBAQ34602510-27A0675D-E276-4482-8D40-DC032D027BCDQ34659682-E58A04F0-962C-4B24-A0D6-B09A703515D4Q34667603-1C8676E2-23D6-45AE-A6C7-1E487BBFF244Q35012513-035639DF-9BC2-43CA-ABCC-7FB4822776E4Q35018157-3909DE35-D8D2-4A62-9E5B-3C8F071CC549Q35172784-FFBC483A-AD06-4A9B-9EF2-1CD6CB3BF868Q35518390-1DEF2AB3-1532-4558-8A34-ACA97985FEFFQ35558344-F9118F6F-CBD4-4153-BEEF-FB14CB6529A3Q35575070-319CCDD7-1AC5-44D8-980D-EA1B1225293EQ35732198-788F4355-01EB-4DCF-B601-168CAE5D4866Q35732239-9066983D-91B3-40A6-A700-F19337C7F601Q35858022-49C1EA28-26A6-4016-B93E-4F91C40DA9F8Q36069611-57101E84-6400-4C6A-96C4-3E74F08A939BQ36081411-0254CD00-B1F9-4202-B0E9-722110C94066Q36118375-C7E301A4-EDFC-499B-8E7D-DF5D461F9299Q36135122-7979A033-1D9B-4244-8C29-2EAE28ECFBA8Q36351270-444A24E7-B3C7-4860-BBC8-960E0630EB36Q36358798-79568DB2-ACD0-48D3-B94E-ABB7EA4EA895Q36513150-C67659D6-5E09-41E6-9B3B-9330A32EF5E6Q36527174-B0CFB3EE-61B0-4302-B229-CFB47FFE5A4CQ36572534-FB52B205-D002-492B-9B34-307817C9619EQ36575166-E4525C4F-DAF3-4714-A370-469BF2D65F1BQ36610042-7E860231-73D7-49A8-8316-E1E595B7312AQ36611886-01D8A881-D290-4129-AEA2-48A531C6DC22Q36619598-2BFFB853-4EAA-45EE-84A9-75FD6B287A93Q36620507-FB994B38-AE37-4CCE-B562-449FD8F584E0Q36621559-E76AA118-582C-4565-9F1E-56AE4761A62F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark Bower
@ast
Mark Bower
@en
Mark Bower
@es
Mark Bower
@sl
type
label
Mark Bower
@ast
Mark Bower
@en
Mark Bower
@es
Mark Bower
@sl
prefLabel
Mark Bower
@ast
Mark Bower
@en
Mark Bower
@es
Mark Bower
@sl
P106
P1153
7007014065
P21
P31
P496
0000-0002-4077-6351